Clinical Trial

Biological and Clinical Efficacy of Shingrix in Patients With CLL

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated May 9, 2024 (before its estimated November 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a biological study. Patients who are eligible to receive Shingrix through the Italian National Health System will be invited to participate in the study. According to AIFA indication, the two doses of vaccine will be administered 4-8 weeks apart. Blood samples will be collected prior to the first vaccine dose (i.e. within the time frame of 3 months prior to the first dose) and 1, 6, 12, 24 and 36 months after the second vaccine dose to evaluate the serological response of Shingrix.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-04-09; most recent amendment 2024-05-08.
Trial Details
NCT Number NCT06364033
Lead Sponsor Gruppo Italiano Malattie EMatologiche dell'Adulto
Conditions Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, CLL-like MBL, Varicella-zoster Virus Reactivation
Enrollment 312 participants
Start Date 2024-08
Primary Completion 2025-11 (estimated)
Study Completion 2028-10 (estimated)
Updated on ClinicalTrials.gov 2024-05-09